Cellectar Biosciences

Company snapshot

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting

• 17 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 US patent(s) indexed to this assignee profile.
• 17 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Cellectar Biosciences. Not investment advice.

• approval Jun 4, 2026

  Cellectar Biosciences (CLRB) FDA Approvals, PDUFA Dates & Drug Alerts 2026

• Peer + 0 momentum

  Chongqing Precision Biotech

  TA overlap score 40

• Peer + 0 momentum

  Teva Pharma

  TA overlap score 40

• Peer + 0 momentum

  Alaunos Therapeutics

  TA overlap score 36.8

• Peer + 0 momentum

  Karyopharm Therapeutics

  TA overlap score 36.4

• Peer + 0 momentum

  Oncolytics Biotech

  TA overlap score 24.6

• Peer + 0 momentum

  Cullinan Therapeutics

  TA overlap score 23.2

• Peer + 0 momentum

  Compass Therapeutics

  TA overlap score 23

• Peer + 0 momentum

  C4 Therapeutics

  TA overlap score 20.8

Recent activity

Latest pipeline, patent, and corporate events for Cellectar Biosciences.

1. Jun 8, 2026 Clinical update

   POTASSIUM IODIDE — Phase 2

2. Jun 8, 2026 Clinical update

   Iopofosine I 131 single dose — Phase 2

3. Jun 8, 2026 Clinical update

   I-131-CLR1404 Injection — Phase 2

4. May 26, 2026 Clinical update

   RNL-Vascostem® — Unknown

5. May 23, 2026 Clinical update

   Paclitaxel — Phase 3

View all clinical trial activity →

• What is Cellectar Biosciences?

  Cellectar Biosciences is a pharma organization headquartered in Florham Park, USA. It trades on NYSE under ticker CLRB. Primary therapeutic focus areas include Waldenstrom Macroglobulinemia, Non Small Cell Lung Cancer, Buerger's Disease, Leukemia, Head and Neck Cancer. NovaPharma

• Is Cellectar Biosciences publicly traded?

  Yes. Cellectar Biosciences is listed with ticker CLRB on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Cellectar Biosciences develop or market?

  We link 7 drug profile(s) where Cellectar Biosciences is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cellectar-biosciences#company-drugs.

• What are the latest developments for Cellectar Biosciences?

  In the last 12 months our linked public records show 17 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Cellectar Biosciences focus on?

  Cellectar Biosciences focuses on Waldenstrom Macroglobulinemia, Non Small Cell Lung Cancer, Buerger's Disease based on our analysis of their pipeline programs and drug development activities.